(Reuters) - Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial officer, Bloomberg Law reported on Tuesday citing one person familiar ...
Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...
Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial ...
Zacks.com on MSN5h
Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...
Birds and humans have different types of receptors in their respiratory tract that flu viruses attach to, like a lock ...
The United Nations Convention on Biological Diversity, or COP16, ended on Nov. 2. Several days before delegations from 177 ...
Advertisement "This research provides valuable insights for policymakers and health communicators as they continue to ...
While it is too early to know how this season’s flu will play out, we do know that COVID-19 is still with us.’ ...
Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...
The biotech industry in Boston is more than just a source of jobs or a pillar of the local economy; it is a powerful force in ...
JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $59 from $70 and keeps an Underweight rating on the shares. The firm updated estimates following Pfizer’s Comirnaty ...
Medpage Today on MSN1d
Year in Review: COVID-19This year's headlines on COVID-19 featured new research on COVID-related mortality, post-acute sequelae of infection, vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback